BioScrip Inc (BIOS) Expected to Post Earnings of -$0.11 Per Share

Equities research analysts expect BioScrip Inc (NASDAQ:BIOS) to post ($0.11) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioScrip’s earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.08). BioScrip reported earnings per share of ($0.16) during the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The business is scheduled to announce its next earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.31) to ($0.21). For the next year, analysts anticipate that the company will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.18) to ($0.14). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow BioScrip.

How to Become a New Pot Stock Millionaire

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, March 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The business had revenue of $182.50 million during the quarter, compared to analysts’ expectations of $171.35 million. During the same quarter last year, the company posted ($0.06) earnings per share. The business’s quarterly revenue was down 24.0% on a year-over-year basis.

BIOS has been the topic of several research reports. BidaskClub raised BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price objective on BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Craig Hallum reaffirmed a “buy” rating and set a $3.50 price objective on shares of BioScrip in a report on Thursday, March 8th. Finally, Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $3.45.

NASDAQ:BIOS traded down $0.09 during trading hours on Monday, hitting $2.55. 1,068,632 shares of the stock were exchanged, compared to its average volume of 960,268. BioScrip has a twelve month low of $1.35 and a twelve month high of $3.39. The company has a debt-to-equity ratio of -5.65, a quick ratio of 1.42 and a current ratio of 1.79. The company has a market cap of $337.12, a price-to-earnings ratio of -5.80 and a beta of 0.11.

Several hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC acquired a new position in shares of BioScrip in the 4th quarter valued at $174,000. Gotham Asset Management LLC acquired a new position in shares of BioScrip in the 4th quarter valued at $114,000. Two Sigma Advisers LP lifted its stake in shares of BioScrip by 100.4% in the 4th quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after purchasing an additional 64,238 shares during the period. Royce & Associates LP lifted its stake in shares of BioScrip by 942.6% in the 4th quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after purchasing an additional 1,649,500 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of BioScrip by 10.2% in the 4th quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock valued at $19,161,000 after purchasing an additional 611,302 shares during the period. 84.29% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “BioScrip Inc (BIOS) Expected to Post Earnings of -$0.11 Per Share” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3344035/bioscrip-inc-bios-expected-to-post-earnings-of-0-11-per-share.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Anticipate First Industrial Realty Trust, Inc.  Will Announce Earnings of $0.38 Per Share
Analysts Anticipate First Industrial Realty Trust, Inc. Will Announce Earnings of $0.38 Per Share
TPI Composites  Expected to Announce Earnings of $0.03 Per Share
TPI Composites Expected to Announce Earnings of $0.03 Per Share
Brokerages Expect Kinsale Capital Group  to Announce $0.36 Earnings Per Share
Brokerages Expect Kinsale Capital Group to Announce $0.36 Earnings Per Share
President Trump  Market Capitalization Reaches $0.00
President Trump Market Capitalization Reaches $0.00
EDRCoin  Tops 24 Hour Volume of $2,782.00
EDRCoin Tops 24 Hour Volume of $2,782.00
WCOIN  Price Hits $0.0991 on Exchanges
WCOIN Price Hits $0.0991 on Exchanges


© 2006-2018 Ticker Report. Google+.